Founded in 1949, Stevanato Group operates globally through two primary business segments: Biopharmaceutical and Diagnostic Solutions (BDS) and Engineering. The BDS segment, which generates the majority of the company's revenue, produces high-value glass containment solutions such as pre-fillable syringes, vials, cartridges, and ampoules, as well as drug delivery systems like pen and auto-injectors. The Engineering segment designs and manufactures specialized machinery for glass tubing conversion, visual inspection, and assembly and packaging processes. The company serves over 700 clients worldwide, including a significant majority of the top pharmaceutical and in-vitro diagnostic companies. Stevanato Group maintains a global footprint with manufacturing and commercial facilities across Europe, North America, South America, and the Asia-Pacific region, including major expansions in the United States and Mexico to support the growing demand for biologics and injectable drugs.
